Israel has signalled it will retaliate but has not said how. EU leaders condemned the Iranian attack, reaffirmed their commitment to Israel's security
Takeda's dengue vaccine wins EU approval
The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue
Published : 8 Dec 2022, 01:02 PM
Updated : 8 Dec 2022, 01:02 PM
Japanese company Takeda's 4502.T dengue vaccine was authorised for use in the European Union on Thursday, making it the second approved vaccine for the mosquito-borne disease that causes millions of infections annually.
The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.
There are no antivirals or specific treatments for the flu-like viral disease. While the illness is mostly mild, some people can develop life-threatening complications. Between 20,000 to 25,000 people, mostly children, die each year, according to the World Health Organisation.
RELATED STORIES
Suu Kyi, 78, has been detained by the Myanmar military since it overthrew her government in a 2021 coup
US stock futures ticked higher after major indexes ended sharply lower on Friday as results from major US banks failed to impress
Oil prices fell more than $1 a barrel on Monday, with Brent sliding under $90, as Middle East tensions eased
